Optimization of Fermentation and Purification Processes for the Production of Linear Covalently Closed DNA Ministrings

安全性高、稳定性好、纯化效率高的DNA载体是基因治疗行业迫切需要的基因载体。迄今为止，虽然许多载体方法已应用于GT，但它们在载体表达传递、持续时间和基因表达效率以及安全性方面存在不足。** **Mediphage Bioceuticals是一家利用噬菌体和/或噬菌体元件开发基因治疗平台技术的初创公司，该公司与兰姆顿学院生物工业过程研究中心合作，优化发酵和纯化过程，以生产线性共价封闭DNA微型载体。****兰姆顿学院的研究团队将与Mediphage Bioceuticals密切合作，包括一名首席研究员和两名研究生。该项目的结果将缓解msDNA生产瓶颈，为细胞工程提供有效和安全的方法，并确保稳定和廉价的载体供应，以实现新的细胞和基因治疗。****

Safer DNA vectors with high stability, efficacy and efficient purification are of high demand in the gene therapy (GT) industry as a delivery device for genetic cargo. To date, while many vector approaches have been applied to GT, they have fallen short in vector expression delivery, duration and gene expression efficiency, and safety.** **Mediphage Bioceuticals, a start-up company that utilizes bacteriophage and/or bacteriophage elements to develop platform technologies for gene therapeutics is partnering with Lambton College's Bio-industrial Process Research centre is to optimize a fermentation and purification process for the production of linear covalently closed DNA minivectors.****The Lambton College research team that will work closely with Mediphage Bioceuticals includes a principal investigator and two research students. The results of the project will relieve the msDNA production bottleneck and provide an efficacious and safe approach to cell engineering, as well as ensure a stable and inexpensive supply of vector to enable new cell and gene therapies.****